Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 4:10 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
The Top 3 Pharma Stocks to Buy in March2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge. 
Via InvestorPlace
3 Dividend Aristocrat Stocks to Buy And Hold: March 2024
Buy-and-holder investors should fill their portfolios with these dividend aristocrat stocks to buy. These are some of the top names in the market. 
Via InvestorPlace
Johnson & Johnson Unusual Options Activity For March 08
Via Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
The Top 3 Healthcare Stocks to Buy in March 2024
There are still bargains to be had in the medical space. These are three top healthcare stocks to buy today. 
Via InvestorPlace
Smart Money Is Betting Big In JNJ Options
Via Benzinga
Beyond The Numbers: 13 Analysts Discuss Johnson & Johnson Stock
Via Benzinga
Evaluating Johnson &amp; Johnson Against Peers In Pharmaceuticals Industry
Via Benzinga
The Top 3 Blue-Chip Stocks to Buy in March 2024
Wager on these top blue-chip stocks to buy, striking an ideal balance between stability and growth for savvy long-term investors. 
Via InvestorPlace
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Johnson & Johnson Completes Acquisition of Ambrx
From Johnson & Johnson
Via Business Wire
The Top 7 Dividend Stocks to Buy in March 2024
Bet on these top dividend stocks to buy for a resilient income flow and steady market gains, offering excellent balance. 
Via InvestorPlace
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
7 No-Frills Dividend Stocks for Your Must-Own List
Income investors don't need to invest in risky businesses when no-frills dividend stocks get the job done just fine. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Secure Your Future: 7 Dividend Kings with Solid Growth Potential
Here are seven dividend kings that manage to deliver market-beating stock price growth in addition to their reliable, growing dividends. 
Via InvestorPlace
Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?
Can Johnson & Johnson stock become a hot buy for growth-focused investors, or is this mainly just a dividend play? 
Via The Motley Fool
Johnson & Johnson Jump?
Johnson and Johnson is coming into a strong seasonal pattern now with an average return of nearly 5%. 
Via Talk Markets
Don’t Panic! 7 Smart Stocks to Buy if the Markets Take a Tumble.
No one wants the red ink to start flying right now. However, if it does, these are the stocks to buy for a down market. 
Via InvestorPlace
Want $1,000 in Ultra-Safe Annual Dividend Income? Invest $19,000 Into the Following 3 Time-Tested Dividend Kings.
These rock-solid dividend stocks, which sport an average yield of 5.26%, have raised their base annual payouts for between 54 and 62 consecutive years. 
Via The Motley Fool
Johnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst
Management's thesis regarding the spinoff is now being tested. 
Via The Motley Fool
Nearing Retirement? These Stocks Are as Cautious as They Come
Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further. 
Via The Motley Fool
7 Dividend Stocks Every Investor Should Own to Survive a Market Crash
Buying dividend stocks for retirement is an excellent way to protect your portfolio in the event of a recession or depression. 
Via InvestorPlace
Topics Economy Retirement
Exposures Economy Pension
5 Most Owned Dividend Aristocrats® by Top Hedge Funds
These five Dividend Aristocrats® all pay safe, reliable, growing dividends. 
Via The Motley Fool
3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount. 
Via InvestorPlace
7 Stocks to Buy Now if You Think the S&P 500’s Winning Streak Will Continue
S&P 500 is hitting new highs and if you want to make the most of this, buy these S&P 500 stocks. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Pension Plan Redux: 3 Companies That Could Take a Page From IBM’s Playbook
A new wrinkle from IBM regarding its pension plans could save the company hundreds of millions in future defined contribution payments. 
Via InvestorPlace
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
FDA Approves Johnson & Johnson's Reduced Tecvayli Dosing In Pretreated Multiple Myeloma Patients
FDA greenlights Johnson & Johnson's Tecvayli for reduced dosing in multiple myeloma patients, achieving complete response for 6+ months. 
Via Benzinga
Exposures Product Safety
2 Beaten-Down Stocks to Buy and Hold for 10 Years
One is a longtime healthcare leader, the other a newcomer; both have bright futures despite recent obstacles. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.